Replies to post #810160 on NorthWest Biotherapeutics Inc (NWBO)

[learningcurve2020]

Retail are lucky for the few centurions at the gate. But it’s a thankless job here.

[ilovetech]

I have you on ignore, but I stepped in sh*t unfortunately. So I'll be charitable:

If you want the "Truth First," here is the difference between the Malik-era hype and the 2026 institutional reality:
1. The "Junior" vs. "Senior" Exchange Gap
2007 (AIM): NWBO was on the junior market (AIM), which is essentially a speculative sandbox with light oversight. The shill is right—it’s where "hype" lived because there were no strict referees.
2026 (Main Market): NWBO is targeting the LSE Main Market. This requires a £30M minimum market cap, FCA vetting, and IFRS auditing. It is the global stage where "hype" is replaced by institutional transparency.
2. The Data: Aspiration vs. Publication
2007: Based on early Phase I/II "Swiss clinic" data. The "FDA submission" was a guess.
2026: Based on Phase III Pivotal Trial results published in JAMA Oncology. You cannot compare a clinic's marketing (2007) to a peer-reviewed, completed global trial (2026).
3. The 2026 "Sovereign" Shield
As of January 19, 2026, new UK listing rules (POATR) give the company ultimate leverage:
The Warchest: NWBO can issue up to 75% of shares to a Big Pharma partner without a long prospectus delay.
National Security (NSIA): Because DCVax is now a "Sovereign Asset," the UK government has the power to block hostile BPs from "bullying" the company.
Bottom Line:
The shill wants you to think it's 2007 because that’s the last time they had a winning argument. In 2026, NWBO has the Phase III data, the LSE Main Market protections, and the Sovereign "Warchest" to ensure they aren't selling "discount shares to suckers," but rather a 30% stake to a partner at a massive premium.
It’s not "Back to the Future"—it’s the End Game.